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Abstract: 
It has been reported that large genomic deletions in the MLH1 and MSH2 genes 
are a frequent cause of Lynch syndrome in certain populations.  
Here, a cohort has been screened and two new founder rearrangements have 
been found in the MSH2 gene. These mutations have been characterized by 
breakpoint determination, haplotype analysis and genotype-phenotype 
correlation. Mutations have been identified in the MLH1, MSH2, and MSH6 
genes in 303 subjects from 160 suspected Lynch syndrome unrelated families.  
All subjects were tested using heteroduplex analysis by capillary array 
electrophoresis (HA-CAE). Multiplex Ligation-Dependent probe amplification 
(MLPA) was used to detect rearrangements in mutation-negative index patients 
and confirmed by RT-PCR. The breakpoint of the deletions was further 
characterized by the Array Comparative Genomic Hybridization (CGH array) 
method. Immunohistochemical (IHQ) staining and microsatellite instability (MSI) 
were studied in tumor samples. Hereditary non-polyposis colorectal cancer 
(HNPCC)-related phenotypes were evaluated.  
More than sixteen percent (24/160) of the families had pathogenic mutations (8 
MLH1, 15 MSH2 and 1 MSH6). Twelve of these families (50%) are carriers of a 
novel mutation. Seven of the fifteen positive MSH2 families (47%) are carriers 
of a rearrangement. The exon 7 deletion and exons 4 to 8 deletion of MSH2 are 
new founder mutations. The segregation of a common haplotype, a similar 
phenotype and anticipation effects were observed in these families.  
These findings will greatly simplify the diagnosis, counselling and clinical care in 
suspected Lynch syndrome families; not only in specific geographical areas, so 
wide distribution may be explained by migration patterns. 
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INTRODUCTION 
Hereditary Nonpolyposis Colorectal Cancer syndrome (HNPCC), or Lynch 
Syndrome (MIM# 120435), is probably the most common form of inherited 
colorectal cancer, accounting for 1%-5% of cases (1). Affected individuals have 
a family history of colorectal cancer (CRC) at an early age, characterized by 
tumor predominance in the proximal colon and an association with extra-colonic 
tumors. Germline mutations in at least five mismatch repair (MMR) genes 
(MLH1, MSH2, MSH6, PMS1 and PMS2)  have  been identified in families 
fulfilling international criteria for the syndrome, namely Amsterdam criteria I or II 
(2,3,4), or less stringent criteria referred to as the Bethesda guidelines (5); 
which lead to tumors characterized by widespread microsatellite instability (MSI).  
Identification of inherited predisposition is important because it enables targeted 
clinical surveillance, which significantly reduces cancer morbidity and mortality 
in Lynch syndrome families (6). 
Nearly 90% of the mutations in databases (Leiden Open Variation Database) 
affect either MLH1 (MIM 120436) or MSH2 (MIM 609309) (7, 8). The vast 
majority are nonsense, missense, splicing or frameshift mutations, but a recent 
report (9) indicates that a substantial percentage of HNPCCs are caused by 
gross genomic rearrangements in MMR gene alterations undetectable with 
traditional methods of mutation analysis. They account for up to 15% of all 
pathogenic mutations in MSH2 and MLH1 (10). The frequency of large 
rearrangements in MSH2 as compared to MLH1 depends on the studied 
population (11). Different pre-screening methods have been proposed. Here a 
combined method of HA-CAE and MLPA has been used to screen our HNPCC 
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population (12). Using this protocol, numerous different mutations have been 
detected and a high proportion has rearrangements, all in the MSH2 gene. 
Two founder mutations in the MSH2 gene are presented and characterized here. 
A similar breakpoint was found in all index cases of the carrier families. These 
mutations appear to be founder effects, as a common haplotype was associated 
with each; besides, the novel exons 4-8 deletion appears to be associated with 
anticipation. 
Our findings have important implications in the diagnosis and management of 
such families and these results will help to simplify genetic testing for Lynch 
Syndrome. 
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PATIENTS AND METHODS 
Participants 
Patients were recruited through the Regional Hereditary Cancer Prevention 
Program of Castilla y León (Spain). Informed consent was obtained from 303 
subjects belonging to 160 unrelated suspected Lynch syndrome families. 
The control population used was from the National DNA Bank a collection of 
representative DNA samples of the Spanish population. 
Available DNA, RNA and tumor blocks were obtained for at least one affected 
person in each family. 
 
Mutation analysis 
Point mutation general screening of the MLH1, MSH2 and MSH6 genes was 
performed using heteroduplex analysis by capillary array electrophoresis (HA-
CAE). This method was developed in our laboratory (13) and the validation for 
MMR genes has recently been published (12). 
Fragments showing an HA-CAE-altered pattern were sequenced with the 
BigDye Terminator Sequencing Kit v3.1 (Applied Biosystems) with unlabelled 
forward and reverse primers on an ABI 3100 DNA sequencer (4 capillaries; 
Applied Biosystems). 
Genomic rearrangement screening 
Negative samples by HA-CAE were tested using MLPA. 
Genomic rearrangements were evaluated by multiplex ligation-dependent probe 
assay (MRC-Holland, Amsterdam, The Netherlands). MLPA test kits P003 for 
MLH1/MSH2 and P008 for MSH6/PMS2 were performed according to the 
supplied protocol. Fragment analysis of the PCR products was carried out on an 
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ABI 3130-Genetic Analyzer and gene dosage calculation and analysis was 
done using GeneMapper software (Applied Biosystems, Foster City, CA). 
Reverse Transcription PCR (RT-PCR) 
All the alterations detected by MLPA were confirmed by RT-PCR. Three 
microliters of total RNA were used to synthesize complementary DNA (cDNA) 
with a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) 
using random primers. RT-PCR was performed with specific primers designed 
for the coding sequences flanking the putative mutation. To confirm deletions, 
short amplicons from RT-PCR were sequenced with the following primers: 
Exon 4-8 deletion: Forward in exon 3: 5´-gttggagttgggtatgtggatt -3´ and Reverse 
in exon 9: 5´-tgttgactgcatcttcttttcc -3´. 
Exon 7 deletion: Forward in exon 6: 5´-tgctgaataagtgtaaaacccc -3´ and Reverse 
in exon 8: 5´-ggagaagtcagaacgaagatcag -3´.  
Immunohistochemical (IHC) and tumor microsatellite instability (MSI) 
testing. 
IHC staining for MLH1, MSH2 and MSH6 genes in tissue from at least one 
individual of the genomic rearrangement families was analyzed by a pathologist 
in the General Yagüe Hospital, Burgos (Spain). 
Paraffin-embedded tumors from these cases were received in our laboratory for 
MSI study.  Paired colon tumor tissues and normal tissues were microdissected 
and DNA extracted using the DNAeasy Tissue kit (Qiagen). A fluorescence 
multiplex polymerase chain reaction to amplify BAT25, BAT26, D2S123, 
D5S346 and D17S250 was carried out as described before (14, 15) with slight 
modifications. Fluorescently labeled PCR products were detected using the ABI 
3130 Genetic Analyzer and the GeneScan software. The tumor was categorized 
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as microsatellite stable if none of the five markers showed instability, as MSI-
low if one of the five markers showed instability, and as MSI-high if two or more 
markers showed instability (14). 
Breakpoint characterization 
A CGH array strategy was done to confirm the deletions identified by MLPA and 
to identify the location of deletion breakpoints. 
One positive sample, from each different family with a rearrangement, was 
tested by a Human Array CGH 44K specially designed by Nimgenetics for 
coverage of chromosome 2: 47419322-47580004 (NCBI 36).  
Based on the information obtained from the CGH array, primers were designed 
spanning the putative breakpoints for each case and used in long-range PCR.  
 
Haplotype analysis 
Index cases and their relatives were genotyped with 8 microsatellite 
polymorphic markers surrounding the MSH2 gene and 2 SNPs in the MSH2 
gene. As controls, 96 unrelated DNA samples from the general population of 
Castilla y Leon (National DNA Bank) were also genotyped, and allele 
frequencies were estimated. 
The ten markers used were localized in a ~3.6 Mb region encompassing MSH2 
(locus order: cen-D2S123-D2S1248-D2S1247-Clen30-rs3771278- rs2162123-
D2S2227-D2S391-Clen27-D2S119-tel) on chromosome 2: 47419322-47580004. 
Fluorescently labeled primers were used to amplify the microsatellite 
polymorphic regions. PCR products were analyzed in a Genetic Analyzer 3130 
using the GenMapper 3.7 software (Applied Biosystems). 
The two intragenic single base substitutions located within intron 1 and intron 9 
of MSH2 (rs2162123 and rs3771278) were screened through High Resolution 
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Melting (HRM) technology [LightCycler® 480 Instrument (Roche)] and samples 
with altered curves were sequenced.  
Phenotypic Characterization 
Genealogical data and phenotype characteristics (gender, age at onset, cancer 
history and characteristic feature of tumors) were evaluated in all 
rearrangement carrier families.  
 
Statistical Method 
Comparisons between mismatch repair mutation types (point mutations versus 
deletions) in the MSH2 gene were assessed using the web resource GraphPad 
Sofware. 
The variables related to the proband family members included type and number 
of colorectal cancer, endometrial cancer and/or other Lynch syndrome related 
cancers and the corresponding ages of diagnosis.  
The number and type of cancers were treated as a categorical variable. 
Categorical data were reported as absolute values (n), relative frequencies (%), 
while groups were compared by analyzing a 2x2 contingency table using 
Fisher's exact test. Age was treated as a continuous variable and thereafter 
dichotomized to <50 or ≥50 years.  Continuous data were reported in mean 
values with their corresponding standard deviation (SD) and groups were 
compared using the Student´s t test. A two-sided P value <0.05 was considered 
statistically significant.  
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RESULTS 
Molecular mutation identification 
A total of 24 families with a pathogenic germline mutation were detected in 
MSH2, MLH1, and MSH6 by combined HA_CAE-MLPA analysis. 
Clinicopathological features, molecular findings of the index patients and 
sample numbers are listed in Table 1. Twelve of these families (50%) are 
carriers of a novel mutation. Seven of them (29.2%) have a rearrangement, all 
in MSH2. Two new rearrangements encompassing exon 7 and exons 4-8 
deletions were detected in three and four non-related families respectively.  
 
Identification of the MSH2 recurrent mutations 
One family had previously been detected with exon 7 deletion and three families 
with exons 4-8 deletion. (The MLPA assay, RT-PCR products and Sequencing 
pattern are in Perez-Cabornero et al. Eur J Cancer, 2009).  New cases of this 
detection are presented here and the recurrence of these mutations and the 
founder effect has been investigated. In total, 4 families (VA17, VA20, VA32 
and VA134) were studied for exons 4-8 deletion; and 3 families (VA4, VA169 
and VA247) for exon 7 deletion. 
Table 1 shows that 58 patients (19% of our tested population) were analyzed for 
a rearrangement, 60% of whom are carriers. 
A high frequency of MSH2 4-8 exons deletion was observed in MSH2 mutation 
carrier families, which accounted for more than 26% (4/15).  
In total, 33 probands were analyzed, 22 of which are carriers and 11 are not 
(double the number of carriers).  
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IHQ and IMS were analyzed in two families and both presented no-staining of 
the MSH2 protein and MSI-H (See Table 1). 
 
Breakpoint identification 
A customized 4x44 Agilent platform was used to map somatic rearrangements 
(Designed by NimGenetics, Spain). The aCGH assay provides a prediction of 
rearrangement breakpoints for the convenient design of primers and 
sequencing. 822 oligonucleotide probes were used to cover MSH2. A median 
distance between non-overlapping array probes of 500 bp was obtained. 
The breakpoints predicted from aCGH are shown in Figure 1. For exon 7, 
aCGH predicts a 0.01Mb deletion at the position 47507393-47515906 and 
presents 71 probes lost (Figure 1.A); for the rearrangement of encoding exons 
4-8, a 0.04 Mb deletion is predicted between positions 47492237-47527926, 
with 284 probes lost (Figure 1.B). 
PCR primers were designed in the first probe before and after the deletion. In 
order to confirm common deletion, PCR was performed for several index cases 
of each family with exon 7 deletion and exons 4-8 deletion. These resulted in a 
deletion product of 36.7Kb in exons 4-8 deletion (g.13272_49953del36681; 
NG_007110.1.gb) and 9.4Kb in exon 7 deletion (g.28106_37472del9366; 
NG_007110.1.gb), exclusively observed in carriers of the common deletion and 
not in deletion-negative controls (See Figures 1.A and 1.B).  
The same mutation was found in exon 7 deletion carrier families and in exon 4-
8 deletion carrier families. The identical breakpoints are positioned within two 
Alu elements (Figures 1A and 1B). Thus, the deletion is likely to have arisen 
through an Alu-mediated recombination. The presence of identical breakpoint 
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sequences in all cases (ID proband in Table 1) is suggestive of a founder 
mutation, since a frequently recurring recombination event would be likely to 
result in at least a few single-nucleotide differences. 
 
 
Haplotype analysis 
Haplotype analysis was performed to confirm the common genetic origin of the 
deletion rearrangements (Figure 2). Most of the positive families for the deletion 
are from a small area in Castilla y León (in central of Spain), ancestors of 
families carrying the exon 4-8 deletion came from Valle de las Navas and exon 
7 deletion ancestors came from Lerma, both in the province of Burgos. 
A shared haplotype was observed cosegregating with the mutation (Figure 2) 
which was absent in non-carriers of these families. It provides evidence for a 
common ancestry among these families. 
Figures 2.1 and 2.2 represent the pedigrees of the four Del4_8 families and the 
three Del_7 families. The phenotype observed in these families is shown as are 
the results of the common haplotype segregation. 
96 unrelated samples were also genotyped as controls and allele frequencies 
were estimated; these are also shown in figures 2.1 and 2.2. 
 
Screening of founder rearrangement deletion in MSH2  
A PCR test was designed to screen these deletions in first degree relatives. A 
routine PCR procedure was optimized. Three primer sequences were used: one 
forward and two reverse. The product is a multiplex PCR with the presence of 
one band in the wild type and two bands in deletion carrier samples (Figure 3). 
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This procedure is faster, cheaper and easier than MLPA. 
  
Genotype-Phenotype correlation  
Taking into account the fact that 62.5% of mutations we have found are in 
MSH2, largely due to the existence of two recurrent mutations in this gene 
which represent approximately half the mutations in MSH2; we have correlated 
the type of mutation (punctual or rearrangement) with the occurrence of 
extracolonic tumors and the age at diagnosis (Table 2). 
The results of table 2 show no differences between the two groups in the 
number of tumors developed (p=1.0000) or the age at diagnosis, using the 
threshold of 50 years (p=1.0000); unlike the tumor type, where the prevalence 
of endometrial and urinary system tumors are higher in founder mutation 
carriers than point mutation carriers (p=0.47279, p=0.1247).  
On the other hand, it must be emphasized that the median age at onset is 
different in both groups; 46.7 years versus 40.67 years in CRC males and 50 
years versus 33 years in CRC females. These data, however, were not 
statistically significant. 
 
DISCUSSION 
Lynch syndrome is a heterogeneous disorder with respect to its molecular basis, 
as well as its phenotypic expression. 
A variety of point mutations, as well as large genomic rearrangements, have 
been reported in the Leiden Open Variation Database (LOVD) (16). 
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Here, 160 families were screened using a combined method previously 
published by our group (12). The overall mutation detection rate in our study is 
15% (24 positive families out of 160). 
 We have found 8 MLH1 mutation carrier families (Table 1), 3 of which have the 
c.306+5G>A mutation, which has been described as a founder mutation in 
Spain, and our group has participated in the work (17). Two truncated mutations 
in exon 1 at MLH1 are novel, both appearing in a proband with colon cancer 
before 50 years of age; while the MLH1_01285 mutation has being described 
by us before (18).   
Only one family is an MSH6 mutation carrier, this is a novel truncated variant. 
The carrier shows a late onset endometrial cancer with absence of any staining 
of the MSH6 protein and MSS tumor. Similar results have been reported in 
several studies (19).  
The higher rate of mutations in this study appears in the MSH2 gene (nearly 
double that in MLH1); this is probably due to the high number of recurrent 
mutations in this gene. 
Two mutations which affect the splicing are reported here and which have been 
described by us in LOVD. The c.1661G>A mutation is present in family VA6, 
which is a large family, and we have studied 44 members, of which 18 are 
carriers (Table 1). This alteration is associated with the absence of 
MSH2/MSH6 staining, MSI-H tumor and a phenotype with colon-rectum cancer 
before the age of 50. The mutation c.2634G>A in exon 15 of MSH2 caused 
endometrial cancer in a mother and her daughter at 43 and 40 years of age, 
respectively.  
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Two recurrent rearrangements have been detected in seven out of fifteen MSH2 
carrier mutation families (more than 46%). Genome rearrangements represent a 
significant proportion of all pathogenic mutations in the MMR genes of patients 
with colon cancer (20). 
An exon 7 deletion was found in three non-related families, the deletion 
producing a change in the reading frame and a truncated protein. Other 
rearrangements in this exon have been described previously (9), but here we 
exactly characterize this mutation in every index case of the three families and 
all of them have the identical mutation and a shared haplotype (Figure 2.1). The 
identification of the breakpoints, within the Y and Sg Alu elements, supports the 
hypothesis that the recurrent exon 7 deletion is due to an Alu repeat mediated 
recombination event. These three families had a high prevalence of colorectal 
cancer, followed by endometrial cancer and prostate tumor, with the majority of 
cancers diagnosed before the age of 50 (Figure 2.1). In recent years, recurring 
mutations for various hereditary cancer syndromes have been identified around 
the world (21). 
The most important evidence in our study is a big deletion that includes five 
exons in the MSH2 gene, an in-frame mutation that produces a shorter protein 
and appears in four non-related Amsterdam criteria fulfilled families. 
The study of the breakpoint in index cases of each of the four families and the 
haplotype analyzed confirms the same mutation in all families (Figure 2.2).  
We identified that another Alu repeat event that was involved in the exon 4-8 
deletion (Figure 2.2). 
The significant proportion of families in our population with one of these founder 
rearrangements (near 50% of the families) suggests the need to design a 
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simpler, faster and cheaper method to detect these mutations. Thus, our 
sample study protocol could be changed and a pre-screening of founder 
mutations can be started.  
We have performed a multiplex PCR (Figure 3) that is cheaper than the MLPA 
method. 
Table 2 describes the cancer types in affected carriers and the average age of 
onset. Most of them developed colon cancer before the age of 45, and the 
women developed endometrial cancer before the age of 50. 
Our data indicate that the anticipation phenomenon is associated with exons 4-
8 MSH2 deletion. This is a subjective observation based on evidence from the 
age of onset and an exhibition of a more aggressive disease severity (number 
of cancers/tumors or the stage of the tumor) over successive generations 
(Figure 2.2). 
The anticipation phenomenon has been described in other syndromes (22). The 
presence of anticipation in HNPCC is more controversial and some reports 
provide significant evidence that MHL1 mutations, in particular, may be 
associated with anticipation (23). Our data suggest that MSH2 deletions may 
well be associated with anticipation effects. The median age at colon cancer 
diagnosis was 44 years in the four families (Table 2), but in family VA20, we 
observed that the difference at onset over two generations was 20 years. In 
family VA17, the number of cancers increased over the generations. 
Both MSH2 rearrangements observed here occurred between intron 4 and 
intron 8. It has been described that this is an Alu rich region, because 
approximately 84% of Alu sequences in MSH2 are located between the 
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promoter and exon 9, and it is possible that these sequences mediate the 
recombination observed in this gene (24, 25). 
Estimating the age of founder mutations is generally an inexact task (26). It was 
therefore impossible to estimate whether all our founder carrier families share 
the same haplotype. The fraction of haplotype can be inadequate for 
recombination events as we have a small number of carrier families and these 
show a short genealogy length. The evidence suggests that the origin of these 
mutations is a recent event. 
Given the high proportion of rearrangements, we have evaluated the phenotype 
in MSH2 mutation carriers. A more severe phenotype (more different tumors, 
less onset, etc.) in rearrangement carriers was expected (25), but differences 
were not found. We only noticed a less primary CRC tumor onset in 
rearrangement carriers than in other MSH2 mutations carriers. 
We detected rearrangements more often in families with endometrial or urinary 
cancer. These data are similar to those published by Geray et al. (27). A 
possible explanation could be that both rearrangements occur in the MSH2 
gene and both are founder mutations in our population. 
The differences found are not statistically significant, and this does not allow us 
to orient the diagnosis based on mutation type (punctual or rearrangement) in 
clinicopathologically suspect patients of MSH2 mutation. 
In conclusion, we have provided genetic evidence that the exon 7 deletion and 
exons 4-8 deletion are both pathogenic founder mutations involved in causing 
HNPCC in a territory in central Spain. Our data show that large genomic 
rearrangements occur in these genes with a high frequency and emphasize the 
need to incorporate techniques to routinely detect them. This should facilitate 
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the genetic diagnosis of Lynch Syndrome in our population. The origin of the 
MSH2 founder rearrangement can be linked to specific geographical areas, and 
their current distribution is compatible with the presumed migration pattern in 
our country. In fact, members of our families have been studied in other cities of 
Spain (Madrid, Barcelona and Sevilla), and it is for this reason that our results 
are very important. 
Our findings will greatly simplify the diagnosis, counseling and clinical care in 
suspected families. 
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Figure legend 
 
Figure 1.A: Exon 7 deletion rearrangement.  a) the breakpoints predicted from 
aCGH; b) rearrangement characterization: PCR amplification, sequencing and 
break point sequence; c) break point location and identification of Alu elements. 
 
Figure 1.B: Exons 4-8 deletion rearrangement.  a) the breakpoints predicted 
from aCGH; b) rearrangement characterization: PCR amplification, sequencing 
and break point sequence; c) break point location and identification of Alu 
elements. 
Figure 2.1: A) marker localization and allele frequency in control population of 
the MSH2 gene in Chromosome 2. B), C) and D) are representative pedigrees 
of exon 7 deletion carrier families. Legend and tumor phenotype are included. 
Figure 2.2: A) marker localization and allele frequency in control population of 
the MSH2 gene in Chromosome 2. B), C), D) and E) are representative 
pedigrees of exons 4-8 deletion carrier families. Legend and tumor phenotype 
are included. 
Figure 3: multiplex PCR of screening rearrangements. A) Exon 7 deletion, the 
wild type samples show one 586 bp band and deletion samples show two 
bands: 586bp and an extra-band of 861bp. B) Exons 4-8 deletion, the wild type 
samples show one 1175 bp band and deletion samples show two bands: 1175 
bp and an extra-band of 751bp. 
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Table legend 
 
Table 1. Pathogenic mutations, clinicopathological features and molecular 
findings of the 24 carrier families. 
 
Table 2. Genotype-Phenotype correlation in MSH2 mutation carriers. 
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Table 1: Pathogenic mutations, Clinicopathological features and molecular findings of the 24 carrier families. 
             
  Family ID Gender 
Cancer site and 
age at diagnosis
Mutation Exon/ Mutation  Mutation Loss of  MSI 
Number of 
carrier 
Number of 
Noncarrier 
Gen code Proband (Male,  designation Intron type status 
protein 
expression status 
      Female)             
MLH1 
VA279 483 M 
Colon 
adenoma , 46 c.23del16; STOP11 E-1 Frameshift NEW MLH1/PMS2- MSI-H 1 2 
VA296 518 M 
Colon 
carcinoma, 36 c.77delA; STOP35 E-1 Frameshift NEW     1   
VA170 300 M 
Colon 
carcinoma, 45 
c.119 delT; 
E-2 Frameshift MLH1_00899     5 3 p.L40fsX 
VA44 77 F 
Rectum,  
c.306+5G>A I-3 Splicing MLH1_00175 MLH1- MSI-H 5 9 27 
VA67 102 M 
Colon 
carcinoma, 59 c.306+5G>A I-3 Splicing MLH1_00175     3 4 
VA175 309 M 
Colon 
carcinoma, 37 c.306+5G>A I-3 Splicing MLH1_00175     3 3 
VA275 429 M 
Colon 
carcinoma, c.1865T>A; 
E-16 
Misssense 
MLH1_00643 MLH1- MSI-H 1   37-42 Leu622His Pathogenic 
VA2 2 M 
Transverse 
Colon, 31 
c.2221-2224 
delCTGC;ins30 E-19 Frameshift 
  
    4 3 
  
MLH1_01285*
MSH2 
VA117 194 F 
Uterine-Colon c.229_230delAG; 
E-2 Frameshift MSH2_00100     5 3 47-53 p.Ser77CysfsX4 
VA22 438 M 
Colon-Rectum c.229_230delAG; 
E-2 Frameshift MSH2_00100 MSH2/MSH6- MSI-H 7 6 43-63 p.Ser77CysfsX4 
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VA17 86 F 
Endometrium c.646-1019_ 
E-4-8 
Exons 4-8 
NEW  MSH2- MSI-H 6 6 
60 1386+2420del deletion 
  p.Ile216_Gln462del   
      
VA20 29 M 
Colon 
carcinoma, 31 
c.646-1019_ 
E-4-8 
Exons 4-8 
NEW      8 2 
1386+2420del deletion 
p.Ile216_Gln462del   
    
VA32 52 F 
Endometrium c.646-1019_ 
E-4-8 
Exons 4-8 
NEW MSH2/MSH6- MSI-H 5 3 
51 1386+2420del deletion 
  p.Ile216_Gln462del   
      
VA134 246 F 
Endometrium c.646-1019_ 
E-4-8 
Exons 4-8 
NEW      3   
42 1386+2420del deletion 
  p.Ile216_Gln462del   
      
VA4 4 F 
Colon 
carcinoma, 39 
c.1077-3513_ 
E-7 
Exon 7 
NEW     8 6 
1276+5655 deletion  
p.R359RfsX16   
    
VA169 299 M 
Colon 
carcinoma c.1077-3513_ 
E-7 
Exon 7 
NEW MSH2/MSH6- MSI-H 1 2 
 29-37 1276+5655 deletion  
  p.R359RfsX16   
      
VA247 413 M 
Colon/ 
Prostate/Urinary c.1077-3513_ 
E-7 
Exon 7 
NEW     4 4 47-57-60 1276+5655 deletion  
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  p.R359RfsX16   
      
VA188 326 F 
Colon 
carcinoma , 68 
c.1226_1227delAG 
E-7   MSH2_00323 MSH2/MSH6- MSI-H 4 2 p.Gln409ArgfsX7 
VA251 432 F 
Colon 
/Endometrium c.1216C>T; 
E-7 Nonsense MSH2_00312     1   23-35 p.Arg406X 
VA6 75 M 
Colon-Rectum C.1661G>A; 
E-10 Splicing 
  
MSH2/MSH6- MSI-H 18 26 
Rectum-Sigma p.Ser554Thr   
47   MSH2_00999*
VA174 305 M 
Colon 
carcinoma , 41 
c.2240_2241delTA  
E-14 Frameshift MSH2_01137 MSH2/MSH6- MSI-H 2   p.Ile747ArgfsX2 
VA199 368 M 
Urinary tract/ 
Colon 
carcinoma ,  c.2470C>T; 
E-15 Nonsense MSH2_01163 MSH2/MSH6- MSI-H 3 2 50-52 p.Gln824X 
VA191 430 F 
Endometrium, c.2634G>A 
E-15 Splicing MSH2_00823     2   40 skipping exon15 
MSH6 VA142 265 F 
Endometrium c.699delT; 
E-4 Frameshift NEW MSH6-   4 1 
Breast STOP245 
59-61   
             
*Mutations  described for us in LOVD                   
In grey: mutations not described before                 
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PUNCTUAL (TRUNCATING) 
REARRANGEMENTS  
(FOUNDER)   
Number of Families 8 7 Statistical 
p-value
Number of affected 19 15 comparison 
Males (%)             10  (52.6)         6 (40)   
  n (%) n (%)   
Number of Tumors        
  1 Tumor 11 (57.9) 8 (53.3) Several Tumors 
1. 0000>1 Tumor  8 (42.1) 7 (46.7)       (yes/no) 
Tumor Type        
    Colon (CRC) 17 (58.6) 13 (50.0)        CRC/EC 0.4727
    Endometrial Cancer (EC) 4 (13.8) 6 (23.1)  
0.1247
    Urinary System (US)  2 (6.9) 7 (26.9)        CRC/US 
Other Cancers (OC)  6 (20.7) -     
Age at diagnosis       
    <50 years 15 (78.9) 11 (73.3%) Age at diagnosis 
<50years(yes/no) 
1. 0000    >50 years 4 (21.1) 4 (26.7%) 
Age at diagnosis Average (SD)* Average (SD)* 
Total (Males and Females) 46.37±10.75 years 40.13±10.46  years Average age 0.0987
CRC (Males) 46.71 ±6.24  years 40.67 ±9.05  years Median age 0.1827
CRC (Females) 50.00±23.72  years 33.00± 6.89  years Median age 0.1657
 Endometrial (Females) 43.00±1.41  years 50.75± 7.37  years Median age 0.2357
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